Abstract
Purpose: Fetal cells in maternal blood are a pure source of fetal genomic DNA for noninvasive prenatal genetic testing (NIPT), if successfully isolated. We assessed whether single-cell genome and transcriptome sequencing (G&T-seq), can isolate fetal nucleated red blood cells (fNRBCs) suitable for genetic testing. Methods: Using umbilical cord blood as a model, we isolated 165 single NRBC candidate cells from four samples, and 12 single lymphocytes as controls from one sample. G&T-seq was used to estimate the maturation stage of each NRBC candidate from the transcriptome data and genomic integrity was assessed using genomic sequencing data. Results: Multi-dimensional scaling (MDS) of the transcriptome data revealed that five NRBC candidate cells clustered separately, classifying them as primitive NRBCs. Two of these cells showed high whole-genome sequencing yields and mapping rates comparable to control lymphocytes, suggesting intact nuclear genome. Conclusions: G&T-seq effectively identified primitive NRBCs with high-quality DNA among candidate cells dominated by mature RBCs. Single-cell multi-omics technology may advance the development of fNRBC-based NIPT.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Center for Child Health and Development of Japan (grant numbers 2023B-8 to KN and 2022A-3 to KH) and MEXT KAKENHI (grant number JP23K15853 to NI).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the National Center for Child Health and Development gave ethical approval (IRB number 699) for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos